Renaissance Technologies LLC grew its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 1,838.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 319,818 shares of the company's stock after buying an additional 303,318 shares during the quarter. Renaissance Technologies LLC owned about 0.14% of Sana Biotechnology worth $521,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in Sana Biotechnology by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company's stock worth $77,000 after purchasing an additional 4,554 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Sana Biotechnology by 20.3% in the fourth quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company's stock valued at $60,000 after buying an additional 6,209 shares during the period. Blue Trust Inc. boosted its stake in Sana Biotechnology by 51.0% during the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock valued at $32,000 after buying an additional 6,694 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Sana Biotechnology in the third quarter worth about $29,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock valued at $1,722,000 after acquiring an additional 8,666 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.
Sana Biotechnology Stock Performance
NASDAQ:SANA traded down $0.01 during trading hours on Wednesday, hitting $1.70. 1,576,421 shares of the company's stock traded hands, compared to its average volume of 3,300,421. Sana Biotechnology, Inc. has a twelve month low of $1.26 and a twelve month high of $10.23. The firm has a market cap of $383.31 million, a P/E ratio of -1.21 and a beta of 1.75. The stock's fifty day moving average price is $1.98 and its two-hundred day moving average price is $2.52.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. On average, equities research analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms recently commented on SANA. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Sana Biotechnology in a research note on Thursday, April 24th. TD Cowen upgraded Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday, January 8th. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a report on Tuesday, March 18th. Finally, Jefferies Financial Group assumed coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a "buy" rating and a $7.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $10.80.
Get Our Latest Analysis on Sana Biotechnology
About Sana Biotechnology
(
Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Further Reading
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
